Orig3n, a Boston, MA-based biotech research company focused on genetics and regenerative medicine, secured Series B funding.
The round, which brings total funding to over $50m to date since inception in 2014, was led by Haitong International with participation from Hatteras Venture Partners, Alexandria Venture Investments, Labcorp, Spectrum Health Ventures, 180 degree capital, VECTR Ventures, KTB Ventures, DEFTA Partners, MMIC Investment Holdings and Mountain Group Partners.
The company intends to use the funds for its international and domestic expansion as well as continued R&D development and advancement of its regenerative medicine treatments using a large allogenic bank of cells that is HLA-matched to 90% of the U.S. population.
Led by Robin Y. Smith, CEO, Orig3n leverages biological science and technology to provide people with access to information about their genes to make proactive and personalized choices that may impact their well-being. The company invests in cell therapy R&D by utilizing cellular science to develop personalized therapies for repairing tissue damage and disease.